Extracellular vesicles in Alzheimer’s disease: Friends or foes? focus on Aβ-vesicle interaction

International Journal of Molecular Sciences

Volumn 16, Issue 3, 2015, Pages 4800-4813

  Joshi, Pooja ^a   Benussi, Luisa ^b   Furlan, Roberto ^c   Ghidoni, Roberta ^b   Verderio, Claudia ^a,d  

^a CNR   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

A assembly; Extracellular Vesicles; Neurodegeneration; Oligomeric A ; Toxcicity

Indexed keywords

ALPHA SYNUCLEIN; AMPA RECEPTOR; AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; FRIZZLED PROTEIN; HUNTINGTIN; INSULIN RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIN RECEPTOR P75; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; CELL MIGRATION; CEREBROSPINAL FLUID; DISEASE SEVERITY; HUMAN; HUNTINGTON CHOREA; MISSENSE MUTATION; NERVE DEGENERATION; PARKINSON DISEASE; REVIEW; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; EXOSOME; MEMBRANE MICROPARTICLE; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL-DERIVED MICROPARTICLES; EXOSOMES; HUMANS; TAU PROTEINS;

EID: 84925883029     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16034800     Document Type: Review

References (73)

1. Filley, C.M. Alzheimer’s disease: It’s irreversible but not untreatable. Geriatrics 1995, 50, 18–23.
2. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913–4917.
3. Masters, C.L.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in alzheimer disease and down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82, 4245–4249.
4. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356.
5. Tapiola, T.; Overmyer M.; Lehtovirta, M.; Helisalmi, S.; Ramberg, J.; Alafuzoff, I.; Riekkinen, P., Sr.; Soininen, H. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer’s disease. Neuroreport 1997, 8, 3961–3963.
6. Wallin, A.K.; Blennow, K.; Andreasen, N.; Minthon, L. Csf biomarkers for Alzheimer’s disease: Levels of β-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 2006, 21, 131–138.
7. Clavaguera, F.; Hench, J.; Goedert, M.; Tolnay, M.: Prion-like transmission and spreading of tau pathology. Neuropathol. Appl. Neurobiol. 2015, 41, 47–58.
8. Brundin, P.; Melki, R.; Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010, 11, 301–307.
9. Nussbaum, J.M.; Schilling, S.; Cynis, H.; Silva, A.; Swanson, E, Wangsanut, T.; Tayler, K.; Wiltgen, B.; Hatami, A.; Rönicke, R. et al.: Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nat. Cell. Biol. 2012, 485, 651–655.
10. Stöhr, J.; Watts, J.C.; Mensinger, Z.L.; Oehler, A.; Grillo, S.K.; DeArmond, S.J.; Prusiner, S.B.; Gilesa, K.: Purified and synthetic Alzheimer’s amyloid β (aβ) prions. Proc. Natl. Acad. Sci. USA 2012, 109, 11025–11030.
11. Avila, J.; Simón, D.; Díaz-Hernández, M.; Pintor, J.; Hernández, F. Sources of extracellular tau and its signaling. J. Alzheimers Dis. 2014, 40, S7–S15.
12. Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B.L.; Lieberburg, I.; Koo, E.H.; Schenk, D.; Teplow, D.B. et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359, 322–325.
13. Sisodia, S.S.: β-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA 1992, 89, 6075–6079.
14. Saido, T.C.; Iwatsubo, T.; Mann, D.M.; Shimada, H.; Ihara, Y.; Kawashima, S. Dominant and differential deposition of distinct β-amyloid peptide species, aβN3(pE), in senile plaques. Neuron 1995, 14, 457–466.
15. Iwatsubo, T.; Saido, T.C.; Mann, D.M.; Lee, V.M.; Trojanowski, J.Q. Full-length amyloid-β (1–42(43)) and amino-terminally modified and truncated amyloid-β 42(43) deposit in diffuse plaques. Am. J. Pathol. 1996, 149, 1823–1830.
16. Russo, C.; Saido, T.C.; DeBusk, L.M.; Tabaton, M.; Gambetti, P.; Teller, J.K. Heterogeneity of water-soluble amyloid β-peptide in alzheimer's disease and down’s syndrome brains. FEBS Lett. 1997, 409, 411–416.
17. Russo, C.; Schettini, G.; Saido, T.C.; Hulette, C.; Lippa, C.; Lannfelt, L.; Ghetti, B.; Gambetti, P.; Tabaton, M.; Teller, J.K. Presenilin-1 mutations in Alzheimer’s disease. Nature 2000, 405, 531–532.
18. Portelius, E.; Bogdanovic, N.; Gustavsson, M.K.; Volkmann, I.; Brinkmalm, G.; Zetterberg, H.; Winblad, B.; Blennow, K. Mass spectrometric characterization of brain amyloid β isoform signatures in familial and sporadic Alzheimer’s disease. Acta Neuropathol. 2010, 120, 185–193.
19. Carecchio, M.; Fenoglio, C.; Cortini, F.; Comi, C.; Benussi, L.; Ghidoni, R.; Borroni, B.; de Riz, M.; Serpente, M.; Cantoni, C. et al. Cerebrospinal fluid biomarkers in progranulin mutations carriers. J. Alzheimers Dis. 2011, 27, 781–790.
20. Portelius, E.; Mattsson, N.; Andreasson, U.; Blennow, K.; Zetterberg, H.: Novel aβ isoforms in Alzheimer’s disease—Their role in diagnosis and treatment. Curr. Pharm. Des. 2011, 17, 2594–2602.
21. Saito, T.; Suemoto, T.; Brouwers, N.; Sleegers, K.; Funamoto, S.; Mihira, N.; Matsuba, Y.; Yamada, K.; Nilsson, P.; Takano, J. et al. Potent amyloidogenicity and pathogenicity of aβ 43. Nat. Neurosci. 2011, 14, 1023–1032.
22. Sandebring, A.; Welander, H.; Winblad, B.; Graff, C.; Tjernberg, L.O. The pathogenic aβ43 is enriched in familial and sporadic Alzheimer disease. PLoS One 2013, 8, e55847.
23. Miravalle, L.; Calero, M.; Takao, M.; Roher, A.E.; Ghetti, B.; Vidal, R. Amino-terminally truncated aβ peptide species are the main component of cotton wool plaques. Biochemistry 2005, 44, 10810–10821.
24. Van Vickle, G.; Esh, C.L.; Kokjohn, T.A.; Patton, R.L.; Kalback, W.M.; Luehrs, D.C.; Beach, T.G.; Newel, A.J.; Lopera, F.; Ghetti, B. et al.: Presenilin-1 280Glu → Ala mutation alters C-terminal APP processing yielding longer aβ peptides: Implications for Alzheimer’s disease. Mol. Med. 2008, 14, 184–194.
25. Kummer, M.P.; Heneka, M.T.: Truncated and modified amyloid-β species. Alzheimers Res. Ther. 2014, 6, 28.
26. Bieschke, J.; Herbst, M.; Wiglenda, T.; Friedrich, R.P.; Boeddrich, A.; Schiele, F.; Kleckers, D.; Lopez del Amo, J.M.; Gruning, B.A.; Wang, Q. et al.: Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat. Chem. Biol. 2012, 8, 93–101.
27. Alzheimer, A.; Stelzmann, R.A.; Schnitzlein, H.N.; Murtagh, F.R. An english translation of Alzheimer’s 1907 paper, “uber eine eigenartige erkankung der hirnrinde”. Clin. Anat. 1995, 8, 429–431.
28. Wyss-Coray, T.; Rogers, T.: Inflammation in alzheimer disease—A brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2012, 2, a006346.
29. Brouillette, J.; Caillierez, R.; Zommer, N.; Alves-Pires, C.; Benilova, I.; Blum, D.; de Strooper, B.; Buee, L.: Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1–42 oligomers are revealed in vivo by using a novel animal model. J. Neurosci. 2012, 32, 7852–7861.
30. Selkoe, D.J.: Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192, 106–113.
31. Perez-Cruz, C.; Nolte, M.W.; van Gaalen, M.M.; Rustay, N.R.; Termont, A.; Tanghe, A.; Kirchhoff, F.; Ebert, U. Reduced spine density in specific regions of ca1 pyramidal neurons in two transgenic mouse models of Alzheimer’s disease. J. Neurosci. 2011, 31, 3926–3934.
32. McLean, C.A.; Cherny, R.A.; Fraser, F.W.; Fuller, S.J.; Smith, M.J.; Beyreuther, K.; Bush, A.I.; Masters, C.L. Soluble pool of aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 1999, 46, 860–866.
33. Benilova, I.; Karran, E.; de Strooper, B. The toxic aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349–357.
34. Rajendran, L.; Annaert, W. Membrane trafficking pathways in Alzheimer’s disease. Traffic 2012, 13, 759–770.
35. Hong, S.; Ostaszewski, B.L.; Yang, T.; O’Malley, T.T.; Jin, M.; Yanagisawa, K.; Li, S.; Bartels, T.; Selkoe, D.J. Soluble aβ oligomers are rapidly sequestered from brain isf in vivo and bind gm1 ganglioside on cellular membranes. Neuron 2014, 82, 308–319.
36. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci. 2007, 8, 499–509.
37. Choy, R.W.; Cheng, Z.; Schekman, R. Amyloid precursor protein (app) traffics from the cell surface via endosomes for amyloid β (aβ) production in the trans-golgi network. Proc. Natl. Acad. Sci. USA 2012, 109, E2077–E2082.
38. Meli, G.; Lecci, A.; Manca, A.; Krako, N.; Albertini, V.; Benussi, L.; Ghidoni, R.; Cattaneo, A. Conformational targeting of intracellular aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat. Commun. 2014, 5, 3867.
39. Mizushima, N.; Komatsu, M. Autophagy: Renovation of cells and tissues. Cell 2011, 147, 728–741.
40. Nilsson, P.; Loganathan, K.; Sekiguchi, M.; Matsuba, Y.; Hui, K.; Tsubuki, S.; Tanaka, M.; Iwata, N.; Saito, T.; Saido, T.C. Aβ secretion and plaque formation depend on autophagy. Cell Rep. 2013, 5, 61–69.
41. Nilsson, P.; Sekiguchi, M.; Akagi, T.; Izumi, S.; Komori, T.; Hui, K.; Sörgjerd, K.; Tanaka, M.; Saito, T.; Iwata, N. et al.: Autophagy-related protein 7 deficiency in amyloid β (aβ) precursor protein transgenic mice decreases aβ in the multivesicular bodies and induces aβ accumulation in the golgi. Am. J. Pathol. 2015, 185, 305–313.
42. Verderio, C.: Extracellular membrane microvesicles and nanotubes in the brain: Understanding their nature, their function in cell-to-cell communication, their role in transcellular spreading of pathological agents and their therapeutic potential. Front. Physiol. 2013, 4, 163.
43. Colombo, E.; Borgiani, B.; Verderio, C.; Furlan, R. Microvesicles: Novel biomarkers for neurological disorders. Front. Physiol. 2012, 3, 63.
44. Vingtdeux, V.; Sergeant, N.; Buee, L. Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer’s disease. Front. Physiol. 2012, 3, 229.
45. Aguzzi, A.; Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64, 783–790.
46. Schneider, A.; Simons, M. Exosomes: Vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 2013, 352, 33–47.
47. Sharples, R.A.; Vella, L.J.; Nisbet, R.M.; Naylor, R.; Perez, K.; Barnham, K.J.; Masters, C.L.; Hill, A.F. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. Faseb J. 2008, 22, 1469–1478.
48. Tamboli, I.Y.; Barth, E.; Christian, L.; Siepmann, M.; Kumar, S.; Singh, S.; Tolksdorf, K.; Heneka, M.T.; Lutjohann, D.; Wunderlich, P. et al.: Statins promote the degradation of extracellular amyloid β-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J. Biol. Chem. 2010, 285, 37405–37414.
49. An, K.; Klyubin, I.; Kim, Y.; Jung, J.H.; Mably, A.J.; O’Dowd, S.T.; Lynch, T.; Kanmert, D.; Lemere, C.A.; Finan, G.M. et al. Exosomes neutralize synaptic-plasticity-disrupting activity of aβ assemblies in vivo. Mol. Brain 2013, 6, 47.
50. Yuyama, K.; Sun, H.; Sakai, S.; Mitsutake, S.; Okada, M.; Tahara, H.; Furukawa, J.; Fujitani, N.; Shinohara, Y.; Igarashi, Y. Decreased amyloid-β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in alzheimer model mice. J. Biol. Chem. 2014, 289, 24488–24498.
51. Dinkins, M.B.; Dasgupta, S.; Wang, G.; Zhu, G.; Bieberich, E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5xfad mouse model of Alzheimer’s disease. Neurobiol. Aging 2014, 35, 1792–1800.
52. Rajendran, L.; Honsho, M.; Zahn, T.R.; Keller, P.; Geiger, K.D.; Verkade, P.; Simons, K.: Alzheimer’s disease β-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. USA 2006, 103, 11172–11177.
53. Vingtdeux, V.; Hamdane, M.; Begard, S.; Loyens, A.; Delacourte, A.; Beauvillain, J.C.; Buee, L.; Marambaud, P.; Sergeant, N. Intracellular ph regulates amyloid precursor protein intracellular domain accumulation. Neurobiol. Dis. 2007, 25, 686–696.
54. Ghidoni, R.; Paterlini, A.; Albertini, V.; Glionna, M.; Monti, E.; Schiaffonati, L.; Benussi, L.; Levy, E.; Binetti, G.: Cystatin c is released in association with exosomes: A new tool of neuronal communication which is unbalanced in Alzheimer’s disease. Neurobiol. Aging 2011, 32, 1435–1442.
55. Perez-Gonzalez, R.; Gauthier, S.A.; Kumar, A.; Levy, E. The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J. Biol. Chem. 2012, 287, 43108–43115.
56. Yuyama, K.; Sun, H.; Mitsutake, S.; Igarashi, Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-β by microglia. J. Biol. Chem. 2012, 287, 10977–10989.
57. Yuyama, K.; Sun, H.; Usukia, S.; Sakaia, S.; Hanamatsua, H.; Miokaa, T.; Kimurac, N.; Okadad, M.; Taharad, H.; Furukawae, J. et al. A potential function for neuronal exosomes: Sequestering intracerebral amyloid-β peptide. FEBS Lett. 2015, 589, 84–88.
58. Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009, 457, 1128–1132.
59. Mattei, V.; Barenco, M.G.; Tasciotti, V.; Garofalo, T.; Longo, A.; Boller, K.; Lower, J.; Misasi, R.; Montrasio, F.; Sorice, M. Paracrine diffusion of prp(c) and propagation of prion infectivity by plasma membrane-derived microvesicles. PLoS One 2009, 4, e5057.
60. Joshi, P.; Turola, E.; Ruiz, A.; Bergami, A.; Libera, D.D.; Benussi, L.; Giussani, P.; Magnani, G.; Comi, G.; Legname, G.; et al. Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2014, 21, 582–593.
61. Del Conde, I.; Shrimpton, C.N.; Thiagarajan, P.; Lopez, J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005, 106, 1604–1611.
62. Shen, B.; Wu, N.; Yang, J.M.; Gould, S.J. Protein targeting to exosomes/microvesicles by plasma membrane anchors. J. Biol. Chem. 2011, 286, 14383–14395.
63. Prada, I.; Furlan, R.; Matteoli, M.; Verderio, C. Classical and unconventional pathways of vesicular release in microglia. Glia 2013, 61, 1003–1017.
64. Martins, I.C.; Kuperstein, I.; Wilkinson, H.; Maes, E.; Vanbrabant, M.; Jonckheere, W.; van Gelder, P.; Hartmann, D.; D’Hooge, R.; de Strooper, B.; et al. Lipids revert inert aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. Embo J. 2008, 27, 224–233.
65. Bellingham, S.A.; Guo, B.B.; Coleman, B.M.; Hill, A.F. Exosomes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front. Physiol. 2012, 3, 124.
66. Ghidoni, R.; Benussi, L.; Binetti, G. Exosomes: The trojan horses of neurodegeneration. Med. Hypotheses 2008, 70, 1226–1227.
67. Agosta, F.; Dalla Libera, D.; Spinelli, E.G.; Finardi, A.; Canu, E.; Bergami, A.; Bocchio Chiavetto, L.; Baronio, M.; Comi, G.; Martino, G. et al. Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and alzheimer disease. Ann. Neurol. 2014, 76, 813-825.
68. Gauthier, S.; Kaur, G.; Mi, W.; Tizon, B.; Levy, E. Protective mechanisms by cystatin c in neurodegenerative diseases. Front. Biosci. 2011, 3, 541–554.
69. Katsuda, T.; Tsuchiya, R.; Kosaka, N.; Yoshioka, Y.; Takagaki, K.; Oki, K.; Takeshita, F.; Sakai, Y.; Kuroda, M.; Ochiya, T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci. Rep. 2013, 3, 1197.
70. Kordelas, L.; Rebmann, V.; Ludwig, A.K.; Radtke, S.; Ruesing, J.; Doeppner, T.R.; Epple, M.; Horn, P.A.; Beelen, D.W.; Giebel, B. Msc-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28, 970–973.
71. Nielsen, H.M.; Mulder, S.D.; Belien, J.A.; Musters, R.J.; Eikelenboom, P.; Veerhuis, R. Astrocytic aβ 1–42 uptake is determined by a β-aggregation state and the presence of amyloid-associated proteins. Glia 2010, 58, 1235–1246.
72. Saman, S.; Kim, W.; Raya, M.; Visnick, Y.; Miro, S.; Jackson, B.; McKee, A.C.; Alvarez, V.E.; Lee, N.C.; Hall, G.F.: Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 2012, 287, 3842–3849.
73. Simon, D.; Garcia-Garcia, E.; Royo, F.; Falcon-Perez, J.M.; Avila, J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012, 586, 47–54.